首页> 美国卫生研究院文献>NPJ Vaccines >Antibody therapies for the prevention and treatment of viral infections
【2h】

Antibody therapies for the prevention and treatment of viral infections

机译:预防和治疗病毒感染的抗体疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.
机译:抗体是宿主对病毒病原体免疫反应的重要组成部分。由于其独特的成熟过程,抗体可以进化为对病毒抗原具有高度特异性的抗体。医师和研究人员一直在依靠如此高的特异性来了解宿主与病毒之间的相互作用以及病毒的发病机理,并找到治疗病毒感染和疾病的潜在方法。在过去的20年中,已开发出60多种重组单克隆抗体供人类使用,现在单克隆抗体被认为是传染病靶标的可行治疗方式,包括新兴的病毒病原体,例如代表日益严重的公共卫生问题的埃博拉病毒,以及人们早已知道诸如人类巨细胞病毒。在这里,我们总结了鉴定和表征单克隆抗体的最新进展,这些单克隆抗体适合作为临床评估的候选药物,并回顾了开发过程中一些有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号